Assyro AI

Orange Book product · Brand (NDA)

QTERN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

Brand (NDA)NDA 209091DISCN ASTRAZENECA AB

At a glance

May 02, 2019

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    May 02, 2019

    7 yr 3 mo ago

  2. Patent 6515117 expires

    Listed drug substance patent expiration.

    Oct 04, 2025

    9 mo ago

  3. Patent 6515117*PED expires

    Listed listed patent expiration.

    Apr 04, 2026

    3 mo ago

  4. Today

  5. Patent 8501698 expires

    Listed drug product patent expiration.

    Jun 20, 2027

    in 1 yr

  6. Patent 8501698*PED expires

    Listed listed patent expiration.

    Dec 20, 2027

    in 1 yr 6 mo

  7. Patent 8221786 expires

    Listed drug product patent expiration.

    Mar 21, 2028

    in 1 yr 9 mo

  8. Patent 8361972 expires

    Listed method-of-use patent (U-493) expiration.

    Mar 21, 2028

    in 1 yr 9 mo

  9. Patent 8716251 expires

    Listed drug product patent expiration.

    Mar 21, 2028

    in 1 yr 9 mo

  10. Patent 8221786*PED expires

    Listed listed patent expiration.

    Sep 21, 2028

    in 2 yr 4 mo

  11. Patent 8361972*PED expires

    Listed listed patent expiration.

    Sep 21, 2028

    in 2 yr 4 mo

  12. Patent 8716251*PED expires

    Listed listed patent expiration.

    Sep 21, 2028

    in 2 yr 4 mo

  13. Patent 7919598 expires

    Listed drug substance patent expiration.

    Dec 16, 2029

    in 3 yr 7 mo

  14. Patent 7919598*PED expires

    Listed listed patent expiration.

    Jun 16, 2030

    in 4 yr 1 mo

Pharmaceutical detail

Active ingredient

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

Strength

5MG;EQ 5MG BASE

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 209091

Product number

002

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
6515117Oct 04, 20259 mo ago
SubstanceProductU-493
6515117*PEDApr 04, 20263 mo ago
8501698Jun 20, 2027in 1 yr
ProductU-493
8501698*PEDDec 20, 2027in 1 yr 6 mo
8221786Mar 21, 2028in 1 yr 9 mo
Product
8361972Mar 21, 2028in 1 yr 9 mo
U-493
8716251Mar 21, 2028in 1 yr 9 mo
Product
8221786*PEDSep 21, 2028in 2 yr 4 mo
8361972*PEDSep 21, 2028in 2 yr 4 mo
8716251*PEDSep 21, 2028in 2 yr 4 mo
7919598Dec 16, 2029in 3 yr 7 mo
Substance
7919598*PEDJun 16, 2030in 4 yr 1 mo
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.